

## LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) IN THE TREATMENT OF THROMBOSIS

René G. Holzheimer

University Halle-Wittenberg, Germany

*Abstract:* Thromboembolic complications are a common and costly medical problem, associated with significant morbidity and mortality, especially in postoperative patients. There have been reports of death due to thromboembolic complications even after short procedures, e.g. arthroscopy. Low-molecular-weight heparins (LMWHs) (e.g., certoparin, dalteparin, enoxaparin, nadroparin, reviparin, tinzaparin) have been tested for treatment of deep vein thrombosis in comparison to unfractionated heparin (UFH) in many patients being effective and safe alternative for treatment of deep vein thrombosis (DVT) and venous thromboembolism (VTE). Fixed-dose subcutaneous LMWH once daily is in most cases of equivalent efficacy and safety compared to conventional UFH therapy. There may be less risk for bleeding, less platelet activation together with a control of markers of haemostatic system activation, and either no progression or regression of thrombus size in patients treated with LMWH. The handling of LMWH is more comfortable for patients and less time consuming for nurses and laboratories compared to UFH. The cost-effectiveness analysis showed that LMWH are more cost effective than UFH. It has been calculated that outpatient treatment with LMWH may save \$ 1641 per patient in comparison to hospital treatment. This economic benefit of outpatient treatment of DVT seems to be realized in different health systems. Women with antiphospholipid antibodies and a history of either prior thrombotic events or pregnancy loss are at high risk during pregnancy for either another fetal death or thrombosis and may benefit from treatment with LMWH. In patients with malignant tumors secondary prophylaxis or long-term treatment with LMWH is successful. Patients with a contraindication for oral anticoagulants may benefit from treatment with LMWH as do patients on chronic anticoagulation treatment scheduled for an operative intervention. In most instances LMWH (dalteparin, enoxaparin, nadroparin) treatment for DVT may be given once daily at a fixed dose without any harm, based on a prolonged antithrombin activity. Effectiveness and safety of LMWH (dalteparin, enoxaparin, nadroparin, tinzaparin) in comparison to UFH treatment on outpatient basis has been demonstrated

in several studies. In summary, LMWHs have an established role in the treatment of DVT and pulmonary embolism (PE), on an in- and outpatient basis and could realize substantial savings. Most studies were performed with dalteparin, enoxaparin and nadroparin. There is evidence that LMWHs may help to prolong survival in cancer patients and to avoid complications of the acute coronary syndrome.

*Key words:* Deep vein thrombosis; pulmonary embolism; dalteparin; enoxaparin; nadroparin; tinzaparin; certoparin; reviparin; LMWH; acute coronary syndrome; cancer

### INTRODUCTION

Thromboembolic complications are a common and costly medical problem, associated with significant morbidity and mortality, especially in postoperative patients. There have been reports of death due to thromboembolic complications even after trivial procedures, e.g. tumescent analgesia and liposuction (Rao et al. 1999). The cause of thrombosis is often unknown but is universally ascribed to part of Virchow's triad: stasis, hypercoagulability, and intimal injury (Quader et al. 1998; Burroughs 1999). In multiple studies LMWHs were successfully tested for prophylaxis of deep vein thrombosis (Holzheimer 2004). The diagnosis of deep vein thrombosis (DVT) requires both clinical assessment and objective testing because clinical features are nonspecific and investigations can be either false positive or negative. Initially the patients are stratified into high-, intermediate- and low-risk categories (Bick and Kaplan 2004). Once a patient is diagnosed with an acute DVT, low-molecular weight heparin (LMWH) is the agent of choice for the initial therapy and oral anticoagulant therapy may follow for long-term secondary prophylaxis. Therapy duration is usually at least three months and may be prolonged depending on the risk of recurrent thrombosis, anticoagulant-related bleeding, and the patient's preference (Hirsh and Lee 2002). Traditionally, treatment for DVT required patients to be hospitalized for administration of intravenous unfractionated heparin, but with years of experience of LMWH treatment, it has

been suggested to initiate or complete therapy in an outpatient setting (Rydberg et al. 1999; Yacovella and Alter 2000). It has been reported that LMWH are potentially superior to unfractionated heparin or warfarin (Hyers 2003). Whereas initial studies have excluded pregnant women and patients with acute pulmonary embolism or a known hypercoagulable disorder, there have been several studies successfully completed in special patient populations in the last decade (Kujovich 1999) and recently more patient populations who may benefit from treatment with LMWH have been identified, e.g., acute coronary syndrome, cancer, stroke, inflammatory bowel disease, pulmonary disease, pregnancy, pulmonary embolism and pediatric patients.

#### THERAPEUTIC EFFICACY AND SAFETY OF LMWH AND UFH

LMWHs (certoparin, dalteparin, enoxaparin, nadroparin, reviparin, tinzaparin) have been tested for treatment of deep vein thrombosis in comparison to UFH in many patients and can be recommended as an effective and safe alternative for treatment of DVT/VTE. Fixed-dose subcutaneous dalteparin once daily is of equivalent efficacy and safety to conventional UFH therapy. There may be less risk for bleeding, less platelet activation together with a control of markers of hemostatic system activation, and no progression of thrombus size. It has been recommended to walk with medical compression stockings which will increase the rate of resolution of pain and swelling (Bratt et al. 1985; Bratt et al. 1988; Albada et al. 1989; Bratt et al. 1990; Hull et al. 1992; Thery et al. 1992; Lindmarker et al. 1994; Meyer et al. 1995; Luomanmaki et al. 1996; Columbus Investigators 1997; Simonneau et al. 1997; Holmstrom et al. 1997; Decousus et al. 1998; Kirchmaier et al. 1998; Partsch and Blattler 2000; Merli et al. 2001; Peternel et al. 2002).

Enoxaparin is at least as effective and safe as UFH. The handling of LMWH is more comfortable for patients and less time consuming for nurses and laboratories (Simonneau et al. 1993; Levine et al. 1996; Xiao and Theroux 1998; Merli et al. 2001). Subcutaneous fixed dose nadroparin is safe and at least as effective as UFH in the treatment of deep vein thrombosis. It significantly inhibits the thrombin and fibrin generation (Lopaciuk et al. 1992; Diquelou et al. 1995). However, UFH may control markers of the hemostatic system more rapidly than once-daily subcutaneously administered weight-adjusted nadroparin (Stricker et al. 1999). LMWH (dalteparin) may exhibit less binding to plasma proteins than unfractionated heparin (Young et al. 1994). In addition to comparability to UFH, LMWHs (reviparin, bemiparin, certoparin) may be more effective in reduction of thrombus size and prevention of recurrent thromboembolism (Kirchmaier et al. 1998; Harenberg et al. 2000; Breddin et al. 2001; Harenberg et al. 2001; Kakkar et al. 2003) (Table 1)

#### THERAPEUTIC EFFICACY AND SAFETY OF LMWH AND COUMARIN/WARFARIN

Most studies comparing LMWH (dalteparin, enoxaparin, nadroparin) with oral anticoagulants (coumarin, warfarin) at least similar efficacy in preventing recurrent DVT (Das et al. 1996; Leroyer et al. 1998; Lopaciuk et al. 1999). Some studies came out with better results for LMWH: less late valvular communicating vein insufficiency (nadroparin) (Lopez-Beret et al. 2001), lower recurrence rate (enoxaparin) of symptomatic venous thromboembolism and lower incidence of bleeding (Gonzalez-Fajardo et al. 1999). However, long-term administration of LMWH (enoxaparin) did not result in lower recurrence rate (Pini et al. 1994) or the findings in elderly patients treated with LMWH (enoxaparin) were inconclusive due to a wide confidence interval for differences between outcomes (Veiga et al. 2000) (Table 2).

#### ARE ALL LMWH EQUAL?

There is insufficient evidence to determine the therapeutic equivalence of LMWHs. Evaluation of clinical trials, also by meta-analysis, is limited because of differing diagnostic methods, drug administration times, dose equivalencies, and outcome measurements. (van der Heijden et al. 2000; McCart 2002).

#### LMWH VERSUS UFH

Several review papers deal with the question whether LMWH should replace unfractionated heparin in the treatment of adults with DVT. Most authors agree that LMWH are at least as effective than UFH but may have less bleeding complications and do not require monitoring (Brewer 1998; Litin 1998; Merli 2000). LMWH preparations vary considerably in their methods of preparation and pharmacological properties, but whether these differences have clinical importance or may help to reduce complications associated with the use of UFH may depend on future trials (Hirsh 1998; Pineo and Hull 1998). Some authors doubt that heparin may prevent recurrence or may decrease thrombus propagation (Egermayer 2001).

#### COST-EFFECTIVE ANALYSIS LMWH VERSUS UFH/OA

The cost-effectiveness analysis showed that LMWH are more cost effective than UFH. Inpatient LMWH treatment became cost saving when it reduced the yearly incidence of late complications by at least 7%, when as few as 8% of patients were treated entirely as outpatients, when at least 13% of patients were eligible for early discharge. It has been suggested that on an outpatient's basis cost of \$1641 per patient could be saved (Rodger et al. 1998; Gould et al. 1999).

Table 1. Randomized studies comparing LMWH and UFH in the treatment of deep vein thrombosis.

Author	Year	Type of LMWH	Efficacy	Comments	Safety
Bratt et al.	1985	Dalteparin	+	No progression of thrombus size in LMWH group (second study)	+
Bratt et al.	1988	Dalteparin	+		+
Albada et al.	1989	Dalteparin	+	Trend in risk reduction for bleeding	+
Bratt et al.	1990	Dalteparin	+	2x/d	+
European multicentre study	1991	Nadroparin	++		+
Prandoni et al.	1992	Nadroparin	+		+
Lopaciuk et al.	1992	Nadroparin	+		+
Hull et al.	1992	Tinzaparin	++		++
They et al.	1992	Nadroparin	+	at 400 anti-Xa	+
DVTENOX study group	1993	Enoxaparin		Hemostatic activation system	
Simonneau et al.	1993	Enoxaparin	++		+
Young et al.	1994	Ardeparin	+	Less plasma protein binding	
Lindmarker et al.	1994	Dalteparin	+	Fixed dose 1/d	+
Diquelou et al.	1995	Nadroparin	++	Similar anticoagulant activity	
Meyer et al.	1995	Dalteparin	+		+
Fiessinger et al.	1996	Dalteparin	+		+
Partsch et al. *	1996	Dalteparin	+	100IU/kg 2x/d better than 200IU/kg 1x/d	+
Luomanmaki et al.	1996	Dalteparin	+	Fixed dose 1x/d	+
Levine et al.	1996	Enoxaparin	+	In- vs out-patient	+
Koopman et al.	1996	Nadroparin	+	In- vs out-patient	+
Holmstrom et al.	1997	Dalteparin	+	1x/d	+
Columbus Investigators	1997	Reviparin	+		+
Simonneau et al.	1997	Tinzaparin	+		+
Xiao and Theroux	1998	Enoxaparin/argatroban	++	UFH is associated with platelet activation	
Kirchmaier et al.	1998	Certoparin	+	s.c. and i.v.	+
Goldhaber et al.	1998	Ardeparin	++	In- vs out-patient	+
Decousus et al.	1998	Enoxaparin	+	Vena cava filter	+
Stricker et al.	1999	Nadroparin		Markers of hemostatic system are more rapidly controlled by UFH	
Belcaro et al.	1999	Nadroparin	+	In- vs out-patient	+
Pernerstorfer et al.	1999	Dalteparin	++	LMWH blunts LPS-induced coagulation activation	
Partsch and Blattler *	2000	Dalteparin		Walking and medical compression stockings improve outcome when added to LMWH	
Harenberg et al.	2000	Certoparin	++		+
Hull et al.	2000	Tinzaparin	++		+
Von Tempelhoff	2000	Certoparin	++	long-term survival breast cancer	+
Harenberg et al.	2001	Certoparin	++	Composite outcome and thrombus size better	++
Merli et al.	2001	Enoxaparin	+	1x/d and 2x/d vs UFH	+
Breddin et al.	2001	Reviparin	++	Better in thrombus reduction and prevention of recurrence	+
Peternel et al.	2002	Dalteparin	+	F1+2, TAT, D-dimers similar	+
Kakkar et al.	2002	Reviparin	++	More effective in inhibiting in vivo thrombin generation than UFH	+
Kakkar et al.	2003	Bemiparin	++	Reduction in thrombus size by bemiparin	+

+ LMWH similar to UFH

++ LMWH better than UFH

\* no UFH

Table 2. Randomized studies comparing LMWH and warfarin/coumarine in the treatment of deep vein thrombosis.

Author	Year	LMWH vs C or W	Efficacy	Comments	Safety
Pini et al.	1994	Enoxaparin vs W	+		++
Das et al.	1996	Dalteparin vs W	+		++
Leroyer et al.	1998	Enoxaparin + C (fluidione) early vs delayed	+	Early and delayed coumarine application have similar outcome	+
Lopaciuk et al.	1999	Nadroparin vs C	+	Secondary prophylaxis	+
Gonzalez-Fajardo et al.	1999	Enoxaparin vs C	++		++
Veiga et al.	2000	Enoxaparin vs C	+	Less bleeding complications	++
Lopez-Beret et al.	2001	Nadroparin vs c	+	Better for recanalization	+

C coumarin

W warfarin

+ LMWH similar to C/W

++ LMWH better than C/W

According to a cost-effective analysis of LMWH versus warfarin for the prevention of secondary thromboembolism LMWH might be a cost-effective drug - depending on the cost for the drug - for secondary prophylaxis, especially in patients at high risk of recurrence (Marchetti et al. 2001).

#### META-ANALYSIS : LMWH VERSUS UFH

A significant reduction in the incidence of thrombus extension but non-significant trends in favour of LMWH were observed for recurrence of thromboembolic events and total mortality in earlier reports on meta-analysis (16 studies) (Leizorovicz et al. 1994). There were relative risk reductions for symptomatic thromboembolic complications (53%), clinically important bleeding (68%), and mortality (47%) when 19 studies were analyzed (Lensing et al. 1995). These results were confirmed in another meta-analysis (Siragusa et al. 1996). However, when inclusion criteria for three major outcomes and randomization procedures were included for evaluation the results were not so straightforward in favor of LMWH. Compared with UFH, LMWH reduced mortality rates over 3 to 6 months of patient's follow-up, but there was no significant difference for bleeding complications and prevention of thromboembolic recurrences (Gould et al. 1999). Clot improvement in venography, recurrence, total mortality and major hemorrhages were assessed in 4,472 patients with DVT from 21 studies treated with LMWH or UFH. LMWH resulted in a significant improvement in clot reduction, a decrease in total mortality, and a lower incidence of hemorrhage. There was no difference in the rate of recurrences (Rocha et al. 2000).

#### LMWH AND DIRECT THROMBIN INHIBITORS OR SYNTHETIC XA-INHIBITOR

LMWHs have been compared to direct thrombin inhibitors and synthetic Xa-inhibitor.

Direct thrombin inhibitor (ximelagatran) shows similar effectiveness in reducing the size of thrombus in patients with deep vein thrombosis when compared to LMWH (dalteparin, enoxaparin) followed by warfarin (Harenberg et al. 2002; Eriksson et al. 2003). Patients treated with a synthetic Xa-inhibitor (fondaparinux) had 2.4% recurrent thromboembolic complications versus 5.0% in the LMWH (dalteparin) group, although not statistically significant. Primary outcome (change in thrombus mass, occurrence of pulmonary embolism (PE)) and safety (bleeding) were similar in both groups (The Rembrandt investigators 2000).

#### EFFECTS OF LMWH IN DIFFERENT CLINICAL SITUATIONS

LMWHs may show activity not only in the haemostatic system, but also in the immune system, which may open new treatment options for these compounds (Pineo and Hull 2004).

In a randomized study comparing LMWH (enoxaparin) versus UFH D-Dimer levels decreased during the first days of treatment and indicated a thromboembolic recurrence, but there was no relationship between antifactor Xa activities and any biological marker (DVTENOX Study Group 1993). Due to the short half-life of the anti-IIa activity of LMWH the effectiveness of LMWH has been difficult to explain (Iorio et al. 1994). The antithrombin III (AT III) mediated anti-Xa and anti-IIa effects have been regarded as the sole determinants of the antithrombotic actions of LMWHs. However, this did not explain the greater than 100% bioavailability of subcutaneously administered LMWH as measured by the chromogenic based antiXa-method. Recently it has been demonstrated that tissue factor pathway inhibitor (TFPI) may explain some of the effects of LMWHs, which induce a distinct TFPI release profile. Long leg compression may also induce an increase in TFPI levels (Hoppensteadt et al.

1995). In a more recent study, LMWH (reviparin) demonstrated to be more effective in inhibiting *in vivo* thrombin generation compared to UFH plus vitamin K antagonist, and it also produced a significantly higher TFPI release and a greater reduction in thrombin activatable fibrinolysis inhibitor (TAFI) and fibrinogen levels (Kakkar et al. 2002). Some patients may not benefit from treatment with LMWH, which may be reflected by a failure of improvement in coagulation parameters, markers of *in-vivo* thrombin generation, TFPI-release and phlebography (Breddin et al. 2003).

#### INFLAMMATION, SEPSIS AND INTENSIVE CARE

LMWHs may demonstrate distinctive anti-inflammatory activities. Lipopolysaccharide (LPS) is a major trigger of sepsis-induced disseminated intravascular coagulation (DIC) via the tissue factor (TF)/factor VIIa-dependent pathway of activation. LMWH may decrease the activation of coagulation caused by LPS, as F (1+2) and polymerized soluble fibrin, termed thrombus precursor protein (TpP) levels were only slightly increased in the LMWH group (Pernerstorfer et al. 1999). LMWH (dalteparin) may attenuate the organ injury after trauma and sepsis by downregulation of TNF-alpha (Tsukuda et al. 2003).

Anticoagulants can influence production of cytokines in whole blood, but the effects vary depending on the type of anticoagulant and the immunological stimulus (Call and Remick 1998). In acute lung injury the protective effects of LMWH may be associated with altered neutrophil adhesion, TNF-alpha and thromboxane activity (Darien et al. 1998). Together with other compounds, e.g., pentoxifylline and dexamethasone, LMWH (enoxaparin) may limit the central nervous system local inflammatory responses and could improve the effort towards reducing the detrimental outcome of patients with pneumococcal meningitis (Schwartz et al. 1998). In acute neurodegenerative diseases LMWH (enoxaparin) may reduce brain edema and the size of lesions, improving motor and cognitive functional recovery (Stutzmann et al. 2002), which may have clinical significance for ischemia and brain trauma. It has been demonstrated that LMWH possesses anti-inflammatory properties distinct from its anticoagulant properties, which may have an effect in ischemia-reperfusion injuries and systemic inflammatory response (Downing et al. 1998; Kruse-Elliott et al. 1998).

#### ALLERGY, AUTOIMMUNE AND INFLAMMATORY BOWEL DISEASE.

Evidence has now accumulated that heparin can significantly affect immune response including allergic inflammation. LMWH may have an inhibitory role in mast cell-mediated allergic inflammation (Baram et al. 1997). Patients with inflammatory bowel disease, in which mast cells play a key role, may benefit from adjuvant treat-

ment with LMWH (He 2004). LMWH (enoxaparin) may ameliorate the severity of colitis (Dotan et al. 2001). It is suggested that LMWHs exert an anti-allergic action by inhibiting infiltration of inflammatory cells, by reducing the release and antagonizing the activities of inflammatory mediators (Wang et al. 2000). Experimental data indicate that antiallergic activity of inhaled heparin is independent of its anticoagulant action and resides in the <2,500 ULMW chains. The antiallergic activity of NAF-heparins is mediated by an unknown biological action and may have therapeutic potential (Campo et al. 1999). Low-molecular-weight heparins may decrease the pathology of T cell-infiltrative autoimmune disease (Christopherson et al. 2002). The enhancement of endothelial cell procoagulant activity by antiphospholipid antibodies has been inhibited by LMWH (Oosting et al. 1992). Women with antiphospholipid antibodies (aPL = IgG anticardiolipin and/or lupus anticoagulants) and a history of either prior thrombotic events or pregnancy loss are at high risk during pregnancy for either another fetal death or thrombosis and may benefit from treatment with LMWH (Cowchock 1998).

#### HEART AND VASCULAR

LMWH may interact with smooth muscle cell migration and proliferation and may alter the accumulation of components of the extracellular matrix after arterial injury. Together with cyclosporine it reduced the frequency and severity of accelerated graft coronary disease and the extent of parenchymal rejection (Aziz et al. 1993). The Factor Xa induced mitogenic response in smooth muscle cells has been inhibited by LMWH (Bretschneider and Schror 2001). LMWH decreased vein wall profibrotic mediators and post-DVT vein wall fibrosis (Thanaporn et al. 2003). Statins and angiotensin converting enzyme (ACE) inhibitors are well known compounds for treatment of coronary artery disease. It has been demonstrated for the first time that a statin, an ACE-inhibitor and a LMWH (dalteparin) suppress tissue factor up-regulation in the cellular micro-environment which may lead to improved treatment of acute coronary syndrome (Lindmark and Siegbahn 2002; Moons et al. 2002). In addition, LMWH (dalteparin) may have further lipolytic effects on serum lipid levels (Myrmet et al. 1992; Monreal et al. 1995).

#### LMWH AND SPECIAL POPULATIONS

LMWHs have been studied in special populations, e.g., elderly or obese patients, which may have clinical implications. The incidence of deep vein thrombosis and pulmonary embolism increases exponentially with age. Careful evaluation of the individual hemorrhagic risk, dose adaptation, and careful laboratory monitoring may help to avoid bleeding complications. LMWH may

offer an advantage but further studies are needed in this population (Gensini et al. 1998). LMWHs may exert a renoprotective effect and cause a reduced platelet activation (Weigert et al. 2001; Stefonié et al. 2002). Obesity and impaired renal function may influence the levels of anti-Xa, although the clinical effect is not yet fully understood. LMWHs have an established role in hemodialysis and hemofiltration, but the reports on their efficacy and safety during continuous renal replacement therapy are scarce (Sagedal and Hartmann 2004). Population analysis in patients with disease and heterogeneity indicated similar pharmacodynamics as in volunteers, supporting weight-based dosing and identified the dependence of clearance on obesity and severe renal function, although the magnitude of these effects are probably not clinically significant (Barrett et al. 2001; Sanderink et al. 2002).

Patients with a contraindication for coumarin use (e.g., recent blood loss, active gastroduodenal ulcer, psychological or physical inability or unwillingness to comply with the laboratory monitoring needs, chronic alcoholism, dementia, pregnancy, recent neurosurgery, pericardial effusion or over 80 years of age) may benefit from LMWH (dalteparin) administration (Monreal et al. 1994). Patients with chronic anticoagulation and the need for an operative intervention may receive LMWH (enoxaparin) treatment (Spandorfer et al. 1999).

#### TIMING AND DOSING OF LMWH

In most instances LMWH (dalteparin, enoxaparin, nadroparin) treatment for DVT may be given once daily at a fixed dose without any harm, which may be possible by a prolonged antithrombin activity (Holmstrom et al. 1992; Alhenc-Gelas et al. 1994; Agnelli et al. 1995; Boneu et al. 1998; Charbonnier et al. 1998; Couturaud et al. 2001; Merli et al. 2001).

#### IN- VERSUS OUT-PATIENT TREATMENT OF DVT

Effectiveness and safety of LMWH (ardeparin, dalteparin, enoxaparin, nadroparin, tinzaparin) in comparison to UFH treatment on outpatient basis has been demonstrated in several studies; however, due to exclusion criteria many patients did not participate (Levine et al. 1996; Goldhaber et al. 1998; Harrison et al. 1998; Wells et al. 1998; Belcaro et al. 1999). The potential savings associated with outpatient DVT treatment are substantial. During a 2-year program evaluation, total cost savings of \$1,108,587 were realized when 391 patients were enrolled in an outpatient treatment program (Tillman et al. 2000). Clinical care pathway using patient selection, an integrated multidisciplinary approach, and the outpatient bleeding risk index may help to provide effectiveness and safety (Vinson and Berman 2001; Wells et al. 2003). Eight studies (three randomized trials and

five cohort studies) compared outpatient use of low molecular weight heparin with inpatient use of unfractionated heparin in 3762 patients. The incidence of recurrent deep venous thrombosis was similar in the two groups (4%), as was major bleeding (0,5%). Use of low molecular weight heparin was associated with shorter hospitalization (median, 2.7 days) versus 6.5 days and lower costs (median difference, 1600 dollars) (Segal et al. 2003). Half of the delays in hospital discharge may be avoided by the outpatient use of LMWH (Dunn et al. 2004). This economic benefit of outpatient treatment of DVT seems to be realized in different health systems (Spyropoulos et al. 2002).

#### UPPER LIMB THROMBOSIS AND LMWH

Upper limb vein thrombosis has been under-recognized, although this disease may pose a significant risk for pulmonary embolism and death. There are only a few reports available dealing with this entity and the use of LMWH (Ellis et al. 2000; Shah and Black-Schaffer 2003).

#### PULMONARY EMBOLISM AND LMWH

Pulmonary embolism may occur in 50% or more of patients with proximal deep vein thrombosis. Even in patients with known proximal DVT symptoms of PE are unspecific (Girard et al. 2001; Pforte 2004). A comparison of LMWH (enoxaparin, tinzaparin, certoparin; nadroparin; reviparin, dalteparin, tinzaparin) with unfractionated heparin or UFH followed by warfarin demonstrated similar effectiveness and safety of LMWH in the treatment of pulmonary embolism (Thery et al. 1992; Meyer et al. 1995; The Columbus Investigators 1997; Simonneau et al. 1997; Decousus et al. 1998; Kirchmaier et al. 1998; Hull et al. 2000; Merli et al. 2001; Findik et al. 2002; Beckman et al. 2003). Fourteen trials investigating the effect of LMWH (nadroparin, tinzaparin, dalteparin, reviparin, certoparin, enoxaparin) were analyzed in a recent meta-analysis. There seems to be a trend for a decrease in recurrent symptomatic venous thromboembolism at the end of treatment and at three months in the LMWH treated patients. Symptomatic and asymptomatic pulmonary embolism and major bleeding complications were reduced, but not statistically significant (Quinlan et al. 2004).

#### SUPERFICIAL THROMBOPHLEBITIS

Superficial thrombophlebitis may bear a risk for deep vein thromboembolic events. However, treatment studies with LMWHs are rare. In a randomized controlled study the following treatment modalities were compared in 562 patients: compression only, early surgery, low-dose subcutaneous heparin, LMWH, and oral anticoagulant treatment. There was no significant difference in DVT incidence at 3 months among the treatment groups. Whereas the cost including LMWH were

the highest in this study, the highest social costs (lost working days, inactivity) were observed in patients treated only with stockings (Belcaro et al. 1999). In a study comparing LMWH (enoxaparin) versus saphenofemoral disconnection no statistically significant differences between the surgery and the LMWH group were discovered (Lozano and Almazan 2003). LMWH (enoxaparin) may reduce the incidence of deep and superficial venous thromboembolism from 30,6% in the placebo group to 8,3%/6,9% in the enoxaparin group (40mg/1,5 mg/kg) (Superficial Thrombophlebitis Treated by Enoxaparin Study Group 2003).

#### ISCHEMIC STROKE AND ATRIAL FIBRILLATION

Deep venous thrombosis (DVT) in the leg occurs in 23% to 75% of patients with acute ischemic stroke, and pulmonary embolism accounts for about 5% of deaths (Bornstein et al. 1988). For patients with ischemic stroke treated within 48 hours of the onset of symptoms, LMWH (nadroparin) was effective in improving outcomes at six months (Kay et al. 1995). The significance of LMWHs for recurrent stroke prevention and for the treatment of stroke-in-progress has been doubted (Sherman 1998). The frequency of recurrent ischemic stroke during the first 14 days was similar in the LMWH (dalteparin) treatment group compared to the aspirin treatment group (Berge et al. 2000). Treatment with other LMWH (tinzaparin), at high or medium dose, within 48 hours of acute ischemic stroke did not improve functional outcome compared with aspirin. Although high-dose tinzaparin was superior in preventing deep-vein thrombosis, it was associated with a higher rate of symptomatic intracranial hemorrhage (Bath et al. 2001). Antithrombotic therapy with LMWH in patients with ischemic stroke needs further evaluation to find out which population may benefit (Busch and Masuhr 2004). Although unproven by randomized studies, LMWH is used as a protective anticoagulant for atrial fibrillation, which may be responsible for a reduction in the length of hospital stay (Kim et al. 2003).

#### CANCER AND LMWH

Cancer cells may be capable of both thrombin formation and induction of fibrin degradation, which may be essential prerequisites for the development of DVT as well as the spread of malignancy. The development of DVT may be indicated by D-dimer and fibrinogen levels may be predictive for the development of DVT (von Tempelhoff et al. 1997; Vukovich et al. 1997). Recurrent venous thromboembolism is more likely to occur in cancer patients (63%) while being treated with warfarin compared to non-cancer patients (30%). It has been suggested that long-term therapy with LMWH (dalteparin) may

be effective in managing warfarin-failure thromboembolic disease (Luk et al. 2001). Warfarin may be associated with a high bleeding rate in patients with VTE and cancer – 6 deaths owing to hemorrhage in the warfarin group compared with none in the LMWH (enoxaparin) group (Meyer et al. 2002). The probability of recurrent thromboembolism at six months was 17% in the oral-anticoagulant group and 9% in the LMWH (dalteparin) group (Lee et al. 2003). Activation of coagulation appears to play a role in tumor progression and time to progression, which may be prolonged by LMWH (enoxaparin) administration (Robert et al. 2003). Certain types of cancer, e.g., breast cancer with unfavorable prognosis, seem to respond positively in terms of survival advantage from treatment with LMWH (certoparin)(von Tempelhoff et al. 2000). Beyond the established use of LMWH in the treatment of thrombosis, recent studies have demonstrated that LMWH therapy can prolong survival in patients with solid tumour malignant disease (Petralia and Kakkar 2004).

#### LMWH IN PREGNANCY

Anticoagulant therapy is indicated during pregnancy for treatment of VTE, systemic embolism in patients with mechanical heart valves, for prevention of pregnancy loss in women with APLAs or previous thrombophilia and previous pregnancy losses (Fiedler and Würfel 2004; Greer 2004). Warfarin may cause embryopathy and CNS abnormalities. There is also a risk of serious perinatal bleeding caused by the trauma of delivery to the anticoagulated fetus (Ginsberg et al. 2001). Especially in anticoagulant factor-deficient women there is an 8-fold risk for venous thromboembolism compared to non-deficient women (Friederich et al. 1996). Consequently, LMWH has been introduced as an alternative treatment option for VTE in pregnancy. Effectiveness and safety of several LMWHs (dalteparin, enoxaparin, tinzaparin) has been evaluated in retrospective or observational studies. Women with a history of venous thromboembolic events have thromboxane dominance during and after pregnancy, which may be eliminated through LMWH (dalteparin) (Kaaja et al. 2001). LMWH (dalteparin) can be used for treatment of acute venous thromboembolism in pregnancy, but at approximately 10-20% higher doses as compared to non-pregnant individuals (Jacobsen et al. 2003). The mean anti-Xa levels may be significantly reduced at 12, 24 and 36 weeks gestation at 2 hours post injection of the LMWH (dalteparin) as compared with the nonpregnant state (Sephton et al. 2003) This has been confirmed for other LMWHs (tinzaparin, enoxaparin) (Casele et al. 1999; Smith et al. 2004), but not all investigators could find a relationship between peak plasma anti-Xa levels of LMWH (enoxaparin) and gestational age (Ellison et al. 2000) There are some reports on side effects, but in most instances they were not related to the use

of LMWH (enoxaparin) (Dulitzki et al. 1996; Ellison et al. 2000; Rodie et al. 2002; Lepercq et al. 2001). Treatment with LMWH plus low-dose aspirin has been proposed as standard therapy for recurrent pregnancy loss due to aPL (Triolo et al. 2003). Despite poorer outcome there was no evidence of greater endothelial cell activation in the treated antiphospholipid syndrome pregnancies (Stone et al. 2003), but there is evidence that LMWH reduce the *in vitro* binding of antiphospholipid antibodies (Franklin and Kutteh 2003). Problematic is the treatment of VTE with LMWH (enoxaparin) in pregnant women with mechanical heart valves (Lev-Ran et al. 2000; Rowan et al. 2001; American College of Obstetrician and Gynecologists 2002) but this critique has not unanimously been accepted and there is an urgent need for clarification of this unresolved issue (Ginsberg et al. 2003). Another unresolved issue is the optimum dosing of LMWH therapy in pregnancy (Bates and Ginsberg 2002).

#### PEDIATRIC PATIENTS AND LMWH

Although thrombosis is less frequent in children than in adults, it represents a significant source of morbidity and mortality. Multiple factors, both genetic and acquired, contribute to the development of thrombosis in children (Hoppe and Matsunaga 2002). In a dose-finding study with two LMWH (enoxaparin) preparations compared to UFH in children with DVT/PE, thrombotic complications in the central nervous system, and congenital heart disease therapy with LMWH was effective and safe. Newborn infants, however, had increased dose requirements (Massicotte et al. 1996). When children with sinovenous thrombosis (SVT) were treated either with LMWH (enoxaparin) or UFH or oral anticoagulants (OA) there were no bleeding events in the LMWH group observed (de Veber et al. 1998). Resolution of thromboembolic events occurred in 94% of children receiving LMWH (enoxaparin); major bleeding in 5% of children receiving therapeutic doses. Recurrent or new thromboembolic events occurred in 1% of children (Dix et al. 2000). Thromboembolic events occurred predominantly in the lower and upper venous system in the presence of indwelling catheters (69%). Preterm infants required higher doses and a longer time to achieve an anti-Xa level in the target range than full term infants. The dose of LMWH (enoxaparin) may be influenced by other factors, e.g., congenital heart disease, impaired liver or renal function. Complete or partial resolution has been achieved in 69% of children with 0.9% of children experiencing a recurrent thromboembolic event and clot extension (Streif et al. 2003). In an open-label randomized trial comparing LMWH (reviparin) versus UFH/OA recurrent thromboembolic events occurred in 5.6% of children at 3 months compared to 10% of children in the UFH/OA group. The incidence of bleeding events was two-

fold in the UFH/OA group (Massicotte et al. 2003).

#### ACUTE CORONARY SYNDROME

Platelet aggregation and activation of coagulation have been recognized as key factors for the development of acute coronary syndromes. Patients suffering from this disease are at high risk of death or myocardial infarction. Heparin is able to reduce this risk in aspirin-treated patients, but is limited in its application by the risk of hemorrhage and thrombocytopenia and patients have to be monitored carefully. LMWHs may present a successful alternative treatment (Turpie and Antman 2001; Bechtold and Janssen 2004). LMWHs (dalteparin, enoxaparin, nadroparin) were found to improve clinical outcomes in acute coronary syndromes and provide a more predictable therapeutic response, longer and more stable anticoagulation, and a lower incidence of UFH-induced thrombocytopenia (Cohen 2003). The American Heart Association and the American College of Cardiology recommend LMWHs for treatment of unstable angina/non-ST-elevation myocardial infarction. Clinical trials with LMWHs showed promising results in patients with percutaneous coronary intervention and ST-elevation myocardial infarction (Wong et al. 2003). However, clinical trials of UFH and LMWH for the treatment of unstable angina may have limited generalizability to unselected patients, many of whom have characteristics that would exclude them from trial enrollment and put them at risk for adverse outcomes (Walsh et al. 2000). In addition, there is some concern about the difference in inclusion and exclusion criteria, and appropriate monitoring of heparin, which may influence outcome observed in some studies (Cohen et al. 1997; Lindahl et al. 2000; Collet et al. 2003; Raschke et al. 2003). Clinical studies demonstrated that lipid-modifying agents (e.g., statins), antiplatelet agents, (e.g., acetylsalicylic acid, glycoprotein IIb/IIIa inhibitors), and low-molecular-weight heparin (e.g., dalteparin, enoxaparin, nadroparin) can reduce the occurrence of acute coronary events in patients with acute coronary syndromes. Angiographic studies suggest that statins may also promote regression of atherosclerosis (Kereiakes 2003; Monroe et al. 2003). There may be an association between atherosclerotic disease and spontaneous venous thrombosis. Atherosclerosis may induce venous thrombosis, or the two conditions may share common risk factors (Prandoni et al. 2003). The instruments for treating acute coronary syndromes, e.g., LMWH may soon be improved. An intensive lipid-lowering statin regimen may provide a greater protection against death or major cardiovascular events in patients with an acute coronary syndrome than does a standard regimen (Cannon et al. 2004).



## REFERENCES

- Agnelli G, Iorio A, Renga C, Boschetti E, Nenci GG, Ofosu FA, Hirsh J. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. *Circulation*. 1995 Nov 15;92(10):2819-24
- Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. *Circulation*. 1989 Oct;80(4): 935-40
- Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin Study Group. *Thromb Haemost*. 1994 Jun;71(6): 698-702
- American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of Lovenox in pregnancy. *Obstet Gynecol*. 2002 Oct;100(4):845-6
- Aziz S, Tada Y, Gordon D, McDonald TO, Fareed J, Verrier ED. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. *J Heart Lung Transplant*. 1993 Jul-Aug;12(4):634-43
- Baram D, Rashkovsky M, Hershkoviz R, Drucker I, Reshef T, Ben-Shitrit S, Mekori YA. Inhibitory effects of low molecular weight heparin on mediator release by mast cells: preferential inhibition of cytokine production and mast cell-dependent cutaneous inflammation. *Clin Exp Immunol*. 1997 Dec;110(3): 485-91
- Barrett JS, Gibiansky E, Hull RD, Planes A, Pentikis H, Hainer JW, Hua TA, Gastonguay M. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. *Int J Clin Pharmacol Ther*. 2001 Oct;39(10): 431-46
- Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. *Blood*. 2002 Nov 15;100(10):3470-8
- Bath PM, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J, O'Neill D, Orgogozo J, Ringelstein B, van der Sande J, Turpie AG. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. *Lancet*. 2001 Sep 1;358(9283):702-10
- Bechtold H, Janssen D. Anticoagulation with low-molecular-weight heparin in patients with heart disease. *Eur J Med Res* 2004;9:186-198
- Beckman JA, Dunn K, Sasahara AA, Goldhaber SZ. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. *Thromb Haemost*. 2003 Jun;89(6):953-8
- Belcaro G, Nicolaidis AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L, Barsotti A, Corsi M, Vasdekis S, Christopoulos D, Lennox A, Malouf M. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. *Angiology*. 1999 Oct;50(10):781-7
- Belcaro G, Nicolaidis AN, Errichi BM, Cesarone MR, De Sanctis MT, Incandela L, Venniker R. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. *Angiology*. 1999 Jul;50(7):523-9
- Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. *Heparin in Acute Embolic Stroke Trial*. *Lancet*. 2000 Apr 8;355(9211):1205-10
- Bick RL, Kaplan BL. Thromboprophylaxis in surgical patients. *Eur J Med Res* 2004;9:104-111
- Boneu B, Navarro C, Cambus JP, Caplain H, d'Azemar P, Necciari J, Duret JP, Gaud C, Sie P. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose. *Thromb Haemost*. 1998 Feb;79(2):338-41
- Bornstein NM, Norris JW. Deep vein thrombosis after ischemic stroke: rationale for a therapeutic trial. *Arch Phys Med Rehabil*. 1988 Nov;69(11):955-8
- Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. *Thromb Haemost*. 1985 Dec 17;54(4):813-7
- Bratt GA, Tornebohm E, Johanson M, Aberg W, Granqvist S, Lockner D. Clinical experiences in the administration of a low molecular weight heparin (Fragmin, Kabi-Vitrum) to healthy volunteers and in the treatment of established deep venous thrombosis. *Acta Chir Scand Suppl*. 1988;543:96-100
- Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). *Thromb Haemost*. 1990 Dec 28;64(4):506-10
- Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV; CORTES Investigators. Clivarin: Assessment of Regression of Thrombosis, Efficacy, and Safety. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. *N Engl J Med*. 2001 Mar 1;344(9):626-31
- Breddin HK, Kadziola Z, Scully M, Nakov R, Misselwitz F, Kakkar VV. Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis. *Thromb Haemost*. 2003 Feb;89(2):272-7
- Bretschneider E, Schror K. Cellular effects of factor Xa on vascular smooth muscle cells-inhibition by heparins? *Semin Thromb Hemost*. 2001 Oct;27(5):489-93.
- Brewer D. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis? *J Fam Pract*. 1998 Sep;47(3):185-92
- Burroughs KE. New considerations in the diagnosis and therapy of deep vein thrombosis. *South Med J*. 1999 May;92(5):517-20.
- Busch M, Masuhr F. Thromboprophylaxis and anti-thrombotic therapy in patients with ischemic stroke and cerebral venous and sinus thrombosis. *Eur J Med Res* 2004;9: 199-206
- Call DR, Remick DG. Low molecular weight heparin is associated with greater cytokine production in a stimulated whole blood model. *Shock*. 1998 Sep;10(3): 192-7
- Campo C, Molinari JF, Ungo J, Ahmed T. Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses. *J Appl Physiol*. 1999 Feb;86(2):549-57
- Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM for the Pravastatin or Atorvastatin

- Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. *New Engl J Med* 2004;350(15):1495-1504
- Casale HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. *Am J Obstet Gynecol.* 1999 Nov;181(5 Pt 1):1113-7
- Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. *Thromb Haemost.* 1998 May;79(5):897-901
- Christopherson KW 2nd, Campbell JJ, Travers JB, Hromas RA. Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. *J Pharmacol Exp Ther.* 2002 Jul;302(1):290-5
- Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmureur J, Bigonzi F, for the Efficacy and Safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. *N Engl J Med* 1997; 337:447-452
- Cohen M. The role of low-molecular-weight heparin in the management of acute coronary syndromes. *J Am Coll Cardiol* 2003;41(4 Suppl S):55S-61S
- Collet JP, Montalescot G, Fine E, Golmard JL, Dalby M, Choussat R, Ankri A, Dumaine R, Lesty C, Vignolles N, Thomas D. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. *J Am Coll Cardiol* 2003; 41(1):8-14
- The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med.* 1997 Sep 4; 337(10): 657-62
- Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. *Thromb Haemost.* 2001 Oct;86(4):980-4
- Cowchock S. Treatment of antiphospholipid syndrome in pregnancy. *Lupus.* 1998;7 Suppl 2:S95-7
- Darien BJ, Fareed J, Centgraf KS, Hart AP, MacWilliams PS, Clayton MK, Wolf H, Kruse-Elliott KT. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. *Shock* 1998;9(4):274-281
- Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. *World J Surg.* 1996 Jun;20(5):521-6
- Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G, for the Prevention du risque d'embolie pulmonaire par interruption cave study group. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. *N Engl J Med* 1998; 338:409-415
- deVeber G, Chan A, Monagle P, Marzinotto V, Armstrong D, Massicotte P, Leaker M, Andrew M. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. *Arch Neurol.* 1998 Dec;55(12):1533-7
- Diquelou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. *Thromb Haemost.* 1995 Nov;74(5): 1286-92
- Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, deVeber G, Leaker M, Chan AK, Massicotte MP. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. *J Pediatr.* 2000 Apr;136(4):439-45
- Dotan I, Hershkoviz R, Karmeli F, Brazowski E, Peled Y, Rachmilewitz D, Halpern Z. Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats. *Aliment Pharmacol Ther.* 2001 Oct;15(10):1687-97
- Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ, Wakefield TW. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. *J Vasc Surg.* 1998 Nov;28(5):848-54
- Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. *Obstet Gynecol.* 1996 Mar;87(3):380-3
- Dunn A, Bioh D, Beran M, Capasso M, Siu A. Effect of intravenous heparin administration on duration of hospitalization. *Mayo Clin Proc.* 2004 Feb;79(2):159-63
- The DVTENOX Study Group. Markers of hemostatic system activation in acute deep venous thrombosis: evolution during the first days of heparin treatment. *Thromb Haemost.* 1993 Dec 20;70(6):909-14
- Egermayer P. The effects of heparin and oral anticoagulants on thrombus propagation and prevention of the postphlebotic syndrome: a critical review of the literature. *Prog Cardiovasc Dis.* 2001 Jul-Aug;44(1):69-80
- Ellis MH, Manor Y, Witz M. Risk factors and management of patients with upper limb deep vein thrombosis. *Chest.* 2000 Jan;117(1):43-6.
- Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. *BJOG.* 2000 Sep;107(9):1116-21
- Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S; Thrive Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. *J Thromb Haemost.* 2003 Jan;1(1):41-7
- European multicentre study. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous fractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. *Thromb Haemost* 1991;65:251-256
- Fiedler K, Würfel W. Effectivity of heparin in assisted reproduction. *Eur J Med Res* 2004;9:207-214
- Findik S, Erkan ML, Selcuk MB, Albayrak S, Atici AG, Doru F. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism. *Respiration.* 2002;69(5):440-4
- Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. *Obstet Gynecol.* 2003 Mar;101(3):455-62
- Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Buller HR, Girolami A, Prins MH. Frequency of pregnancy-related venous thromboembolism in anti-coagulant factor-deficient women: implications for prophylaxis. *Ann Intern Med.* 1996 Dec 15;125(12):955-60
- Gensini GF, Rostagno C, Cacioli S. Treatment options for acute venous thromboembolism in the older patient. *Geriatrics.* 1998 Jan;53(1):34-6, 39-40, 46-7

- Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. *Chest*. 2001 Jan;119(1 Suppl): 122S-131S
- Ginsberg JS, Chan WS, Bates SM, Kaatz S. Anticoagulation of pregnant women with mechanical heart valves. *Arch Intern Med*. 2003 Mar 24;163(6): 694-8
- Girard P, Decousus M, Laporte S, Buchmuller A, Herve P, Lamer C, Parent F, Tardy B; PREPIC Study Group. Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. *Am J Respir Crit Care Med*. 2001 Sep 15;164(6):1033-7
- Goldhaber SZ, Morrison RB, Diran LL, Creager MA, Lee TH Jr. Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin. *Arch Intern Med*. 1998 Nov 23;158(21):2325-8
- Gonzalez-Fajardo JA, Arreba E, Castrodeza J, Perez JL, Fernandez L, Agunde I, Mateo AM, Carrera S, Gutierrez V, Vaquero C. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. *J Vasc Surg*. 1999 Aug;30(2):283-92
- Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. *Ann Intern Med*. 1999 May 18;130(10):789-99
- Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. *Ann Intern Med*. 1999 May 18;130(10):800-9
- Greer IA. Prevention of venous thromboembolism in pregnancy. *Eur J Med Res* 2004;9:135-145
- Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Buller HR. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. *Thromb Haemost*. 2000 May;83(5):652-6
- Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin. *Semin Thromb Hemost*. 2001 Oct;27(5):513-8
- Harenberg J, Ingrid J, Tivadar F. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. *Isr Med Assoc J*. 2002 Nov;4(11): 1003-5
- Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. *Arch Intern Med* 1998;158:2001-2003
- He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. *World J Gastroenterol*. 2004 Feb 1;10(3):309-18
- Hirsh J. Low-molecular-weight heparin for the treatment of venous thromboembolism. *Am Heart J*. 1998 Jun;135(6 Pt 3 Su):S336-42
- Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. *Blood*. 2002 May 1;99(9):3102-10
- Holmstrom M, Berglund MC, Granqvist S, Bratt G, Tornebohm E, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. *Thromb Res*. 1992 Jul 1;67(1): 49-55
- Holmstrom M, Lindmarker P, Granqvist S, Johnsson H, Lockner D. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis. *Thromb Haemost*. 1997 Aug;78(2):803-7
- Holzheimer RG. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH). *Eur J Med Res* 2004;9:150-170
- Hoppe C, Matsunaga A. Pediatric thrombosis. *Pediatr Clin North Am*. 2002 Dec;49(6):1257-83
- Hoppensteadt DA, Jeske W, Fareed J, Bermes EW Jr. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. *Blood Coagul Fibrinolysis*. 1995 Jun;6 Suppl 1:S57-64
- Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. *N Engl J Med* 1992;326:975-982
- Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, Gottschalk A, Valentine KA, Mah AF, for the American-Canadian Thrombosis Study Group. Low-molecular-weight heparin in the treatment of patients with pulmonary embolism. *Arch Intern Med* 2000;160:229-236
- Hyers TM. Management of venous thromboembolism: past, present, and future. *Arch Intern Med*. 2003 Apr 14;163(7):759-68
- Iorio A, Alatri A, Mazzolai L, Agnelli G. Plasma thrombin neutralization assay: pharmacokinetic applications. *Semin Thromb Hemost*. 1994;20(3):266-73
- Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. *BJOG*. 2003 Feb;110(2):139-44
- Kaaja R, Pettila V, Leinonen P, Ylikorkala O. Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins. *Br J Haematol*. 2001 Sep;114(3):655-9
- Kakkar VV, Hoppensteadt DA, Fareed J, Kadziola Z, Scully M, Nakov R, Breddin HK. Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. *Blood*. 2002 Mar 15;99(6):1965-70
- Kakkar VV, Gebaska M, Kadziola Z, Saba N, Carrasco P; Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. *Thromb Haemost*. 2003 Apr;89(4):674-80
- Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A. Low-molecular-weight heparin for the treatment of acute ischemic stroke. *N Engl J Med*. 1995 Dec 14;333(24): 1588-93
- Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. *Circulation* 2003;108(16 Suppl 1):III22-7
- Kim MH, Decena BF, Bruckman D, Eagle KA. Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. *Am Heart J*. 2003 Apr;145(4): 665-9
- Kirchmaier CM, Wolf H, Schafer H, Ehlers B, Breddin HK. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. *Int Angiol*. 1998 Sep;17(3): 135-45

- Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, D'Azemar P, Büller HR, for the TASMAR study group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. *N Engl J Med* 1996;334:682-687
- Kruse-Elliott KT, Chaban K, Grossman JE, Tomasko S, Kamke C, Darien B. Low molecular weight heparin alters porcine neutrophil responses to platelet-activating factor. *Shock*. 1998 Sep;10(3):198-202
- Kujovich JL. Low-molecular-weight heparin: more indications for use. *Hosp Pract (Off Ed)*. 1999 Apr 15;34(4):67-8, 71-8
- Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med*. 2003 Jul 10;349(2):146-53
- Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. *BMJ*. 1994 Jul 30;309(6950):299-304
- Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. *Arch Intern Med*. 1995 Mar 27;155(6):601-7
- Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. *BJOG*. 2001 Nov;108(11):1134-40
- Leroyer C, Bressollette L, Oger E, Mansourati J, Cheze-Le Rest C, Nonent M, Buchmuller A, Tardy B, Decousus H, Parent F, Simonneau G, Juste K, Ill P, Abgrall JF, Clavier J, Mottier D. Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group. *Haemostasis*. 1998 Mar-Apr;28(2):70-7
- Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med*. 1996 Mar 14;334(11):677-81
- Lev-Ran O, Kramer A, Gurevitch J, Shapira I, Mohr R. Low-molecular-weight heparin for prosthetic heart valves: treatment failure. *Ann Thorac Surg*. 2000 Jan;69(1):264-5
- Lindahl B, Toss H, Siegbahn A, Per Venge, Wallentin L, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. *N Engl J Med* 2000;343:1139-1147
- Lindmark E, Siegbahn A. Tissue factor regulation and cytokine expression in monocyte-endothelial cell cocultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. *Thromb Res*. 2002 Oct 1;108(1):77-84.
- Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. *Thromb Haemost*. 1994 Aug;72(2):186-90
- Litin SC, Heit JA, Mees KA. Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease: answers to frequently asked questions. The Thrombophilia Center Investigators. *Mayo Clin Proc*. 1998 Jun;73(6):545-50
- Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, Bielawiec M, Glowinski S, Czestochowska E. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. *Thromb Haemost*. 1992 Jul 6;68(1):14-8
- Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora A. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. *Thromb Haemost*. 1999 Jan;81(1):26-31
- Lopez-Beret P, Orgaz A, Fontcuberta J, Doblaz M, Martinez A, Lozano G, Romero A. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. *J Vasc Surg*. 2001 Jan;33(1):77-90
- Lozano FS, Almazan A. Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. *Vasc Endovascular Surg*. 2003 Nov-Dec;37(6):415-20
- Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. *Am J Med*. 2001 Sep;111(4):270-3
- Luomanmaki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, Kiviniemi H, Koskivirta H, Sorskog L, Vilkkio P. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. *J Intern Med*. 1996 Aug;240(2):85-92
- Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. *Am J Med*. 2001 Aug;111(2):130-9
- Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. *J Pediatr*. 1996 Mar;128(3):313-8
- Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Andrew M; RE-VIVE Study Group. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. *Thromb Res*. 2003 Jan 25;109(2-3):85-92
- McCart GM, Kayser SR. Therapeutic equivalency of low-molecular-weight heparins. *Ann Pharmacother*. 2002 Jun;36(6):1042-57
- Merli GJ. Low-molecular-weight heparins versus unfractionated heparin in the treatment of deep vein thrombosis and pulmonary embolism. *Am J Phys Med Rehabil*. 2000 Sep-Oct;79(5 Suppl):S9-16

- Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilka K; Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. *Ann Intern Med.* 2001 Feb 6;134(3):191-202
- Meyer G, Brenot F, Pacouret G, Simonneau G, Gillet Juvin K, Charbonnier B, et al. Subcutaneous low-molecular weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism : an open randomized pilot study. *Thromb Haemost.* 1995;74:1432-1435
- Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. *Arch Intern Med.* 2002 Aug 12-26;162(15):1729-35
- Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. *Thromb Haemost.* 1994 Jan;71(1):7-11
- Monreal M, Lafoz E, Urrutia A, Roncales J, Galimany R, Biosca C, Corominas A. Effects of long-term therapy with either heparin or low-molecular-weight heparin on serum lipid levels. A prospective study. *Haemostasis.* 1995 Nov-Dec;25(6):283-7
- Monroe VS, Kerensky RA, Rivera E, Smith KM, Pepine CJ. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes. *J Am Coll Cardiol* 2003;41(4 Suppl S):23S-30S
- Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. *Cardiovasc Res.* 2002 Feb 1;53(2):313-25
- Myrnel T, Larsen TS, Reikeras O. Lipolytic effect of low-molecular-weight-heparin (Fragmin) and heparin/dihydroergotamine in thromboprophylactic doses during total hip replacement. *Scand J Clin Lab Invest.* 1992 Nov;52(7):741-5.
- Oosting JD, Derksen RH, Blokzijl L, Sixma JJ, de Groot PG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity-studies in a thrombosis model. *Thromb Haemost.* 1992 Sep 7;68(3):278-84
- Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. *J Vasc Surg.* 2000 Nov;32(5):861-9
- Pernerstorfer T, Hollenstein U, Hansen J, Knechteldorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B. Heparin blunts endotoxin-induced coagulation activation. *Circulation.* 1999 Dec 21-28;100(25):2485-90
- Peternel P, Terbizan M, Tratar G, Bozic M, Horvat D, Salobir B, Stegnar M. Markers of hemostatic system activation during treatment of deep vein thrombosis with sub-cutaneous unfractionated or low-molecular weight heparin. *Thromb Res.* 2002 Feb 1;105(3):241-6
- Petralia G, Kakkar AK. Antithrombotic therapy with low molecular weight heparin in cancer patients. *Eur J Med Res* 2004;9:119-124
- Pforte A. Epidemiology, diagnosis, and therapy of pulmonary embolism. *Eur J Med Res* 2004;9:171-179
- Pineo GF, Hull RD. Unfractionated and low-molecular-weight heparin. Comparisons and current recommendations. *Med Clin North Am.* 1998 May;82(3):587-99
- Pineo GF, Hull RD. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. *Eur J Med Res* 2004;9:215-224
- Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. *Thromb Haemost.* 1994 Aug;72(2):191-7
- Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. *Lancet.* 1992 Feb 22;339(8791):441-5
- Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AWA, Prins MH, Girolami A. An association between atherosclerosis and venous thrombosis. *N Engl J Med* 2003;348:1435-1441
- Quader MA, Stump LS, Sumpio BE. Low molecular weight heparins: current use and indications. *J Am Coll Surg.* 1998 Dec;187(6):641-58
- Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. *Ann Intern Med.* 2004 Feb 3;140(3):175-83
- Rao RB, Ely SF, Hoffman RS. Deaths related to liposuction. *N Engl J Med* 1999;340:1471-1475
- Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. *Ann Intern Med* 2003;138(9):720-723
- The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. *Circulation.* 2000 Nov 28;102(22):2726-31
- Robert F, Busby E, Marques MB, Reynolds RE, Carey DE. Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. *Lung Cancer.* 2003 Nov;42(2):237-45
- Rocha E, Martinez-Gonzalez MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. *Haematologica.* 2000 Sep;85(9):935-42
- Rodger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. *CMAJ.* 1998 Oct 20;159(8):931-8
- Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. *BJOG.* 2002 Sep;109(9):1020-4
- Rowan JA, McCowan LM, Raudkivi PJ, North RA. Enoxaparin treatment in women with mechanical heart valves during pregnancy. *Am J Obstet Gynecol.* 2001 Sep;185(3):633-7
- Rydberg EJ, Westfall JM, Nicholas RA. Low-molecular-weight heparin in preventing and treating DVT. *Am Fam Physician.* 1999 Mar 15;59(6):1607-12
- Sagedal S, Hartmann A. Low molecular weight heparins as thromboprophylaxis in patients undergoing hemodialysis/hemofiltration or continuous renal replacement therapies. *Eur J Med Res* 2004;9:125-130

- Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U, Montay G, Boutouyrie B, Miro A. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. *Clin Pharmacol Ther.* 2002 Sep;72(3):308-18
- Schwartz D, Engelhard D, Gallily R, Matoth I, Brenner T. Glial cells production of inflammatory mediators induced by *Streptococcus pneumoniae*: inhibition by pentoxifylline, low-molecular-weight heparin and dexamethasone. *J Neurol Sci* 1998;155(1):13-22
- Segal JB, Bolger DT, Jenckes MW, Krishnan JA, Streiff MB, Eng J, Tamariz LJ, Bass EB. Outpatient therapy with low molecular weight heparin for the treatment of venous thromboembolism: a review of efficacy, safety, and costs. *Am J Med.* 2003 Sep;115(4):298-308
- Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, Toh CH. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. *Obstet Gynecol.* 2003 Jun;101(6):1307-11
- Shah MK, Black-Schaffer RM. Treatment of upper limb deep vein thrombosis with low molecular weight heparin. *Am J Phys Med Rehabil.* 2003 May;82(5):415-7
- Sherman DG. Heparin and heparinoids in stroke. *Neurology.* 1998 Sep;51(3 Suppl 3):S56-8
- Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. *Arch Intern Med.* 1993 Jul 12;153(13):1541-6
- Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. *Tinzaparin ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.* *N Engl J Med.* 1997 Sep 4;337(10):663-9
- Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. *Am J Med.* 1996 Mar;100(3):269-77
- Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. *Am J Obstet Gynecol.* 2004 Feb;190(2):495-501
- Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. *Am J Cardiol.* 1999 Aug 15;84(4):478-80
- Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. *Chest.* 2002 Jul;122(1):108-14
- Stefoni S, Cianciolo G, Donati G, Coli L, La Manna G, Raimondi C, Dalmastrì V, Orlandi V, D'Addio F. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. *Nephron.* 2002;92(3):589-600
- Stone S, Hunt BJ, Seed PT, Parmar K, Khamashta MA, Poston L. Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy. *Am J Obstet Gynecol.* 2003 Feb;188(2):454-60
- Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. *Arch Dis Child Fetal Neonatal Ed.* 2003 Sep;88(5):F365-70
- Stricker H, Marchetti O, Haeberli A, Mombelli G. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis. *Thromb Haemost.* 1999 Oct;82(4):1227-31
- Stutzmann JM, Mary V, Wahl F, Grosjean-Piot O, Uzan A, Pratt J. Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury: a review. *CNS Drug Rev* 2002;8(1):1-30
- Superficial Thrombophlebitis Treated By Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a non-steroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. *Arch Intern Med.* 2003 Jul 28;163(14):1657-63
- Thanaporn P, Myers DD, Wroblewski SK, Hawley AE, Farris DM, Wakefield TW, Henke PK. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. *Surgery.* 2003 Aug;134(2):365-71
- Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. *Circulation* 1992; 85: 1380-1389
- Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. *Arch Intern Med.* 2000 Oct 23;160(19):2926-32
- Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, Giarratano A, Li-cata G. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. *Arthritis Rheum.* 2003 Mar;48(3):728-31
- Tsukada S, Enomoto N, Takei Y, Hirose M, Ikejima K, Kitamura T, Sato N. Dalteparin sodium prevents liver injury due to lipopolysaccharide in rat through suppression of tumor necrosis factor-alpha production by Kupffer cells. *Alcohol Clin Exp Res.* 2003 Aug;27(8 Suppl):7S-11S
- Turpie AG, Antman EM. Low-molecular weight heparins in the treatment of acute coronary syndromes. *Arch Intern Med* 2001;161(12):1484-1490
- van der Heijden JF, Prins MH, Buller HR. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? *Thromb Res.* 2000 Oct 15;100(2):V121-30
- Veiga F, Escriba A, Maluenda MP, Lopez Rubio M, Margalet I, Lezana A, Gallego J, Ribera JM. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (aceno-coumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. *Thromb Haemost.* 2000 Oct;84(4):559-64
- Vinson DR, Berman DA. Outpatient treatment of deep venous thrombosis: a clinical care pathway managed by the emergency department. *Ann Emerg Med.* 2001 Mar;37(3):251-8
- von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. *Thromb Haemost.* 1997 Mar;77(3):456-61

- von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. *Int J Oncol.* 2000 Apr;16(4):815-24
- Vukovich TC, Gabriel A, Schaeffer B, Veitl M, Matula C, Spiss CK. Hemostasis activation in patients undergoing brain tumor surgery. *J Neurosurg.* 1997 Oct;87(4):508-11
- Walsh CR, Lloyd-Jones DM, Camargo CA, Giugliano RP, O'Donnell CJ. Clinical trials of unfractionated heparin and low-molecular-weight heparin in addition to aspirin for the treatment of unstable angina pectoris: do the results apply to all patients? *Am J Cardiol* 2000;86(9):908-912
- Wang QL, Shang XY, Zhang SL, Ji JB, Cheng YN, Meng YJ, Zhu YJ. Effects of inhaled low molecular weight heparin on airway allergic inflammation in aerosol-ovalbumin-sensitized guinea pigs. *Jpn J Pharmacol.* 2000 Apr;82(4):326-30
- Weigert C, Brodbeck K, Haring HU, Gambaro G, Schleicher ED. Low-molecular-weight heparin prevents high glucose- and phorbol ester-induced TGF-beta 1 gene activation. *Kidney Int.* 2001 Sep;60(3):935-43
- Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, Kovacs J. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. *Arch Intern Med.* 1998 Sep 14;158(16):1809-12
- Wells PS, Forgie MA, Simms M, Greene A, Touchie D, Lewis G, Anderson J, Rodger MA. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. *Arch Intern Med.* 2003 Apr 28;163(8):917-20
- Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. *JAMA* 2003;289(3):331-342
- Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. *Circulation.* 1998 Jan 27;97(3):251-6
- Yacovella T, Alter M. Anticoagulation for venous thromboembolism. What are the current options? *Postgrad Med.* 2000 Sep 15;108(4):43-6, 51-4
- Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. *Thromb Haemost.* 1994 Mar;71(3):300-4

*Received: April 6, 2004 / Accepted: April 15, 2004*

*Address for correspondence:*

René G. Holzheimer MD PhD  
Blombergstr. 5  
D-82054 Sauerlach Germany  
Tel. + + 49-8104-887822  
Fax + + 49-8104-887824  
Gresser.holzheimer@t-online.de  
www.praxisklinik-sauerlach.de